Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.
2.

Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia.

Zhao Y, Sun P, Watson P, Mitchell B, Swindle R.

Pain Pract. 2011 May-Jun;11(3):204-16. doi: 10.1111/j.1533-2500.2010.00412.x. Epub 2010 Aug 27.

PMID:
20807351
3.

Real-world comparison of health care utilization between duloxetine and pregabalin initiators with fibromyalgia.

Peng X, Sun P, Novick D, Andrews J, Sun S.

J Pain Res. 2014 Jan 9;7:37-46. doi: 10.2147/JPR.S51636. eCollection 2014.

4.

Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.

Zhao Y, Sun P, Watson P.

Curr Med Res Opin. 2011 Apr;27(4):785-92. doi: 10.1185/03007995.2011.554807. Epub 2011 Feb 8.

PMID:
21303196
5.

Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators.

Sun P, Peng X, Sun S, Novick D, Faries DE, Andrews JS, Wohlreich MM, Wu A.

Pain Pract. 2014 Jan;14(1):22-31. doi: 10.1111/papr.12044. Epub 2013 Mar 14.

PMID:
23489659
6.

Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia.

Sun P, Zhao Y, Zhao Z, Watson P.

Curr Med Res Opin. 2011 Sep;27(9):1793-801. doi: 10.1185/03007995.2011.605113. Epub 2011 Aug 3.

PMID:
21810060
7.

Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine.

Burke JP, Sanchez RJ, Joshi AV, Cappelleri JC, Kulakodlu M, Halpern R.

Pain Pract. 2012 Mar;12(3):209-18. doi: 10.1111/j.1533-2500.2011.00478.x. Epub 2011 Jun 16.

PMID:
21676163
8.

Predictors of pain medication selection among patients diagnosed with fibromyalgia.

Boulanger L, Wu N, Chen SY, Nagar S, Fraser K, Bernauer MJ, Zhao Z, Zhao Y.

Pain Pract. 2012 Apr;12(4):266-75. doi: 10.1111/j.1533-2500.2011.00497.x. Epub 2011 Sep 8.

PMID:
21899718
9.

Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia.

Kim SC, Landon JE, Lee YC.

Arthritis Res Ther. 2015 Jan 28;17:18. doi: 10.1186/s13075-015-0530-8.

10.

Factors associated with pain medication selection among patients diagnosed with diabetic peripheral neuropathic pain: a retrospective study.

Chen S, Wu N, Boulanger L, Fraser K, Zhao Z, Zhao Y.

J Med Econ. 2011;14(4):411-20. doi: 10.3111/13696998.2011.585676. Epub 2011 May 26.

PMID:
21615268
11.

Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine.

Zhao Y, Chen SY, Wu N, Fraser KA, Boulanger L.

Pain Pract. 2011 Jul-Aug;11(4):381-91. doi: 10.1111/j.1533-2500.2010.00431.x. Epub 2010 Dec 29.

PMID:
21199311
12.

Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care.

Gore M, Tai KS, Chandran A, Zlateva G, Leslie D.

J Med Econ. 2012;15(1):19-31. doi: 10.3111/13696998.2011.629262. Epub 2011 Oct 20.

PMID:
21970699
13.

Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine.

Harnett J, Margolis J, Cao Z, Fowler R, Sanchez RJ, Mardekian J, Silverman SL.

Pain Pract. 2011 May-Jun;11(3):217-29. doi: 10.1111/j.1533-2500.2010.00440.x. Epub 2010 Dec 28.

PMID:
21199319
14.

Impact of potential pregabalin or duloxetine drug-drug interactions on health care costs and utilization among Medicare members with fibromyalgia.

Ellis JJ, Sadosky AB, Ten Eyck LL, Cappelleri JC, Brown CR, Suehs BT, Parsons B.

Clinicoecon Outcomes Res. 2014 Oct 14;6:389-99. doi: 10.2147/CEOR.S66759. eCollection 2014.

15.

Health care costs in patients with fibromyalgia on pregabalin vs. duloxetine.

Burke JP, Sanchez RJ, Joshi AV, Cappelleri JC, Kulakodlu M, Halpern R.

Pain Pract. 2012 Jan;12(1):14-22. doi: 10.1111/j.1533-2500.2011.00470.x. Epub 2011 May 26.

PMID:
21615857
16.

Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care.

Gore M, Zlateva G, Tai KS, Chandran AB, Leslie D.

Pain Pract. 2011 Mar-Apr;11(2):167-79. doi: 10.1111/j.1533-2500.2010.00415.x. Epub 2010 Aug 17.

PMID:
20723096
17.

A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine.

Ellis JJ, Sadosky AB, Ten Eyck LL, Mudumby P, Cappelleri JC, Ndehi L, Suehs BT, Parsons B.

BMC Health Serv Res. 2015 Apr 15;15:159. doi: 10.1186/s12913-015-0829-9.

18.

Healthcare utilization and costs of patients with rosacea in an insured population.

Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G.

J Drugs Dermatol. 2008 Jan;7(1):41-9.

PMID:
18246697
19.

Dosing pattern comparison between duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain.

Sun P, Zhao Y, Zhao Z, Bernauer M, Watson P.

Pain Pract. 2012 Nov;12(8):641-8. doi: 10.1111/j.1533-2500.2012.00537.x. Epub 2012 Feb 15.

PMID:
22335435
20.

Comparing clinical and economic characteristics between commercially-insured patients with diabetic neuropathy and demographically-matched diabetic controls.

Zhao Y, Ye W, Le TK, Boye KS, Holcombe JH, Swindle R.

Curr Med Res Opin. 2009 Mar;25(3):585-97. doi: 10.1185/03007990802706289 .

PMID:
19232033
Items per page

Supplemental Content

Write to the Help Desk